Rheumatology and Orthopedics· Topic 17.4 Rheumatoid arthritis· 17.4.1

Rheumatoid arthritis

Rheumatoid arthritis is a chronic systemic autoimmune disease causing symmetric small-joint polyarthritis of the hands and feet that spares the distal interphalangeal joints, with morning stiffness over an hour. Diagnosis combines the ACR/EULAR classification criteria with rheumatoid factor, anti-CCP antibody, and radiographs. Treat-to-target management anchors on methotrexate, escalating to a biologic or targeted synthetic disease-modifying antirheumatic drug when remission is not reached.

13 min read18 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: rheumatoid arthritis (RA) is a chronic systemic autoimmune disease in which loss of tolerance to citrullinated self-proteins drives inflammatory polyarthritis in genetically susceptible people.

  • Epidemiology

    Prevalence: 0.5% to 1% of the general population.

  • Risk factors

    Genetic susceptibility: HLA-DRB1 shared epitope alleles bind and present citrullinated peptide antigens; about 100 non-HLA loci also contribute.

  • Pathophysiology

    Loss of tolerance: PAD converts arginine to citrulline, generating citrullinated peptides that are immunogenic in people with the shared epitope; the resulting autoantibodies can predate clinical arthritis by years.

  • Clinical features

    Joint distribution: symmetric arthritis of the MCP, PIP, and wrist joints of the hands and metatarsophalangeal (MTP) joints of the feet, sparing the DIP joints; larger joints can also be involved…

  • Differential diagnosis

    Osteoarthritis: DIP, PIP, and first carpometacarpal predominance with stiffness under 30 minutes and no systemic inflammation, unlike DIP-sparing RA (osteoarthritis).

  • Diagnosis

    Classify using the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria: in a patient with at least one joint showing definite synovitis not better explained…

  • Management

    First-line, start a conventional synthetic DMARD as soon as RA is diagnosed: Methotrexate, the anchor drug: 7.5 to 10 mg PO once weekly, titrated by 2.5 to 5 mg every 2 to 4 weeks to 15 to 25 mg once…

  • Complications

    Atlantoaxial subluxation: C1-C2 involvement occurs in up to 50% of chronic RA on flexion-extension radiographs; dens erosion can compress the cord or brainstem, so cervical stability must be assessed before intubation.

  • Prognosis

    Erosive risk concentrates in seropositive disease: persistent polyarthritis with elevated acute-phase reactants and a positive rheumatoid factor or anti-CCP predicts erosion within 1 to 2 years.

  • Prevention

    Smoking cessation is the single most important modifiable risk-reduction measure, particularly with a family history of RA.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.